ICICI Securities has given a buy call for Akums Drugs & Pharmaceuticals with a target price of Rs 710, citing profitable growth potential. ...

Akums Drugs & Pharmaceuticals has signed a long-term contract worth Rs 1760 crore with an unnamed global pharmaceutical company to manufact...

Akums Drugs and Pharmaceuticals saw its shares rise 8% to Rs 784.6 on its debut, despite a strong subscription rate of 63.44 times. Analyst...

Akums Drugs and Pharmaceuticals' shares began trading at Rs 725, a 6.8% premium over the issue price of Rs 679, after an IPO that was subsc...

Akums Drugs and Pharmaceuticals will debut on Tuesday. The stock, with a GMP of Rs 140, is expected to list at a 21% premium over the upper...

Akums Drugs & Pharma share allotment has been finalised. Shares will be out on August 6. The IPO was subscribed 63.5 times. Proceeds will a...

Non-institutional investors subscribed 22.8 times, followed by retail investors, whose category was booked 13.8 times. The part reserved fo...

In the unlisted market, shares of the company are currently commanding a premium of 26% over the IPO price, with GMP of Rs 175. The IPO its...

Akums Drugs IPO Review GMP, Subs: Akums Drugs and Pharmaceuticals' IPO, valued at Rs 1,857 crore, closed on August 1. The issue included Rs...

Akums Drugs and Pharma's IPO, open from July 30 to August 1, targets raising Rs 1857 crore. The company specializes in pharmaceutical devel...

Analysts said India's capital markets are playing a vital role in the country's growth, thanks to advancements in technology, innovation, a...

Akums Drugs and Pharma IPO: Akum Drugs and Pharmaceuticals set a price band of Rs 646 to Rs 679 per share for its IPO, aiming to raise Rs 1...

Akums' introduction of a cost-effective hydroxyurea oral solution for sickle cell disease, offered to GoI, has the potential to transform t...

This association is set to bring succour in therapy areas of CNS disorders, pain management, and hormonal disorders, where there is a gap i...

Looming expiry of tax incentives, rising raw material costs and a fluctuating rupee add to pharma contract manufacturers' woes.

The market size of the segment is expected to be about $7.3 billion (Rs 45,300 crore) for 2013, according to Revati Kasture.

HC has granted a temporary relief to Troikaa restraining two pharma companies from making & selling the patented versions of diclofenac inj...